Sentences with word «abiraterone»

We carried out a multicentre single - arm phase II trial in women with AR - positive, estrogen, progesterone receptor and HER2 - negative (triple - negative) metastatic or inoperable locally advanced BC to assess the efficacy and safety of abiraterone acetate (AA) plus prednisone.

Among the group of men who had non-metastatic and metastatic disease who had not received prior treatment with abiraterone and enzalutamide, data for 60 were available for analysis.

A one - month supply of the recommended dose of abiraterone costs $ 8,000 to $ 11,000 when purchased wholesale.

The time to confirmed PSA progression was 14.9 months for enzalutamide and 10.2 months for abiraterone / prednisone (hazard ratio [HR], 0.83; 95 % CI, 0.55 — 1.25; P =.372).

Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent, according to the results of one of the largest ever clinical trials for prostate cancer presented at the 2017 ASCO Annual Meeting in Chicago and published in the New England Journal of Medicine.

A PSA decline rate of 50 % or greater was seen in 77 % of patients assigned enzalutamide compared with 55 % of patients assigned abiraterone / prednisone (P =.0012).

«Cancer Research UK scientists first discovered abiraterone and subsequently played a key role in its development, including funding the first clinical trials.

The results from the Cancer Research UK - funded STAMPEDE trial could change the standard of care for men with prostate cancer, making abiraterone a first - line treatment alongside hormone therapy.

Abiraterone goes further and shuts down the production of the hormones that fuel prostate cancer's growth.

In men who were given abiraterone there was a 70 per cent reduction in disease progression.

As part of the trial, I started taking abiraterone four times a day and had a hormone injection every eight weeks.

While the outlook of patients with this gene variant is poor, these studies offer hope for a new treatment strategy for these men, and more studies are needed using next - generation androgen inhibitors, such as abiraterone and enzalutamide.

Abiraterone works by blocking CYP17A1, an enzyme that is crucial for the production of androgens.

They found that 12 patients on active abiraterone therapy had detectable serum levels of D4A.

Furthermore, they found that D4A is more effective than abiraterone at killing aggressive prostate cancer cells, suggesting that some patients may benefit from direct treatment with D4A.

Subjects must have progressed on prior new hormonal agent (e.g. abiraterone acetate and / or enzalutamide) for the treatment of mCRPC.

Professor de Bono has led ground - breaking clinical trials testing new treatments for men with this disease, for example abiraterone, cabazitaxel and enzalutamide.

A new study found that patients with mCRPC had higher PSA response with enzalutamide vs abiraterone, but no difference in time to progression, and reported worse outcomes in those with quantifiable ctDNA.

Abiraterone -LSB-...]

Patients with metastatic castration - resistant prostate cancer (CRPC) had higher prostate - specific antigen (PSA) response when treated with enzalutamide compared with abiraterone / prednisone, but had no difference in time to progression or time to PSA progression, according to the results of a study (abstract 5002) presented by Kim N. Chi, MD, of the British Columbia Cancer Agency in Vancouver, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2 — 6.

«Adding abiraterone to standard treatment improves prostate cancer survival by 40 percent.»

A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration - Resistant Prostate Cancer who have Failed Prior Treatment with a New Hormonal Agent and have Homologous Recombination Repair Gene Mutations.

The amount of abiraterone that gets absorbed and enters the blood stream can be multiplied four or five times if the drug is swallowed with a low - fat meal (7 percent fat, about 300 calories).

In addition, 20 % of patients assigned abiraterone had a rising PSA as best response compared with 10 % of patients assigned enzalutamide (P =.0501).

This suggests that the presence of AR - V7 in circulating tumour cells does not preclude response to galeterone as has been shown to be the case for abiraterone and enzalutamide.»

Several clinical centres in the USA and Canada recruited four groups of men with CRPC to a phase II study to receive 2550 mg of galeterone orally once a day: 22 men had CRPC that had not metastasised (spread) and had received no previous treatment; 39 men had metastatic CRPC and no previous treatment with abiraterone or enzalutamide; 37 and nine men had metastatic CRPC and had failed treatment with abiraterone and enzalutamide respectively.

«Recent data have shown that a variant of the androgen receptor called AR - V7, found in tumour cells circulating in the blood of patients with metastatic CRPC, predicted resistance to treatment with enzalutamide and abiraterone,» she will say.

Half the men were treated with hormone therapy while the other half received hormone therapy and abiraterone.

Among patients who were resistant to abiraterone, 37 were available for evaluation; 13 out of 37 (35 %) had any PSA decline.

Associate professor Mary - Ellen Taplin, of the Dana - Farber Cancer Institute, Boston, USA, will tell the 26th EORTC - NCI - AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, that galeterone was well tolerated by patients in the ARMOR2 trial, and also lowered PSA levels in a subset of men with CRPC that was resistant to other drugs that target the cancer, such as enzalutamide and abiraterone.

«Abiraterone is already used to treat some men whose disease has spread but our results show many more could benefit.

Abiraterone acetate, marketed as Zytiga ®, is the standard medicine used to treat metastatic castration - resistant prostate cancer.

Abiraterone, approved in 2011 for the treatment of metastatic prostate cancer, has a «food effect» that is greater than any other marketed drug.

Abiraterone, taken with prednisone to prevent side effects, «represents a new standard of care for metastatic disease,» according to a recent review article in the New England Journal of Medicine.

Abiraterone's ability to lower levels of prostate - specific antigen, a surrogate marker for prostate cancer, was slightly greater for patients in the low - dose with food group when measured at 12 weeks.

Patients with metastatic prostate cancer who have not yet been treated with chemotherapy will be given either the second - line hormone therapy abiraterone, or abiraterone in combination with cabazitaxel.

D4A levels varied among patients, however, suggesting that individuals may differ in their metabolism of abiraterone to D4A.

This 41 percent PSA response rate to taxane therapy is notable because the PSA response rate to abiraterone or enzalutamide in AR - V7 - positive patients was 0 percent in the authors» prior study.

Cleveland Clinic researchers have discovered for the first time that a metabolite of an FDA - approved drug for metastatic prostate cancer, abiraterone (Abi), has more anti-cancer properties than its precursor.

Cleveland Clinic researcher Nima Sharifi, M.D., found that abiraterone, a steroid inhibitor, is converted into the more physiologically active D4A (Δ4 - abiraterone) in both patients and animal models with prostate cancer who take the drug.

«More studies are needed to uncover the exact mechanisms involved, but we predict that direct treatment with D4A could prolong survival in some patients with metastatic prostate cancer,» said Dr. Sharifi, «Further studies will also help us develop a potential biomarker profile to predict which patients will respond to D4 — abiraterone.»

The results showed that adding abiraterone and the steroid prednisolone to standard hormone therapy extended the lives of these men.

This phase II study included 202 treatment - naive patients and randomly assigned them to abiraterone or enzalutamide with crossover at PSA progression.

Abiraterone plus prednisolone / prednisone, or docetaxel, combined with ADT may be the most effective therapies for metastatic hormone - naive prostate cancer.

Abiraterone / prednisone and enzalutamide are both first - line therapies for treatment of metastatic CRPC but no trials to date have compared them head to head.

Similarly, the time to unconfirmed PSA progression was 8.0 months for enzalutamide compared with 7.4 months for abiraterone (HR, 0.83; 95 % CI, 0.59 — 1.17; P =.283).

Patients treated with abiraterone had hypertension, hypokalemia, and elevated liver enzymes.

Patient 2 was diagnosed with widespread metastatic prostate cancer in 2013 and progressed on numerous systemic therapies, including leuprolide, bicalutamide, enzalutamide, abiraterone, and eventually docetaxel.